Suppr超能文献

发育中的、发育异常的和恶性口腔上皮中的ERBB受体。

ERBB receptors in developing, dysplastic and malignant oral epithelia.

作者信息

Rautava J, Jee K J, Miettinen P J, Nagy B, Myllykangas S, Odell E W, Soukka T, Morgan P R, Heikinheimo K

机构信息

Department of Oral and Maxillofacial Surgery, Institute of Dentistry, University of Turku, Lemminkäisenkatu 2, Fin-20520, Turku, Finland.

出版信息

Oral Oncol. 2008 Mar;44(3):227-35. doi: 10.1016/j.oraloncology.2007.02.012. Epub 2007 Jun 28.

Abstract

Some oral squamous cell carcinomas (OSCCs) overexpress epidermal growth factor receptor (EGFR) but little is known about the receptor system overall during oral carcinogenesis. We studied all four ERBB receptors (EGFR, ERBB2-4) in developing (n=2), normal (n=7), dysplastic (n=23) and malignant (n=26) oral epithelia by means of immunohistochemistry. The investigations were supplemented by conducting reverse transcription-polymerase chain reactions in relation to 13 OSCC samples. All four ERBB receptors were detected in developing oral epithelium and, to a lesser degree, in mature oral epithelium. An increase in EGFR immunoreactivity was seen in 61% and 54% of dysplasias and OSCCs, respectively. The corresponding percentages for ERBB2 were 48 and 12, for ERBB3 48 and 43. ERBB4 nuclear staining was increased in 30% of dysplasias and 26% of OSCCs. Changes in ERBB receptor mRNA levels were not statistically significant. The results show that ERBB receptor profiles are specific to each tumour. Increased nuclear translocation of ERBB4 in some OSCCs may alter transcription of target genes and be associated with cancer progression. This information may be useful for clinicians as EGFR inhibitors are becoming treatment options in modern oncology.

摘要

一些口腔鳞状细胞癌(OSCC)过度表达表皮生长因子受体(EGFR),但在口腔癌发生过程中,人们对整个受体系统的了解甚少。我们通过免疫组织化学方法研究了发育中的(n = 2)、正常的(n = 7)、发育异常的(n = 23)和恶性的(n = 26)口腔上皮中的所有四种ERBB受体(EGFR、ERBB2 - 4)。通过对13个OSCC样本进行逆转录 - 聚合酶链反应来补充研究。在发育中的口腔上皮中检测到了所有四种ERBB受体,在成熟口腔上皮中的表达程度较低。在发育异常和OSCC中,EGFR免疫反应性分别在61%和54%的病例中增加。ERBB2的相应百分比分别为48%和12%,ERBB3为48%和43%。在30%的发育异常和26%的OSCC中,ERBB4核染色增加。ERBB受体mRNA水平的变化无统计学意义。结果表明,ERBB受体谱因肿瘤而异。在一些OSCC中,ERBB4核转位增加可能会改变靶基因的转录,并与癌症进展相关。由于EGFR抑制剂正在成为现代肿瘤学中的治疗选择,这一信息可能对临床医生有用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验